December 3, 2018 Yes, today was the last full day of ASH, but that’s not to say it wasn’t full of information with oral presentations packing the day from 7:00 a.m.–7:45 p.m. Highlights included (# abstract number): Isatuximab-Vel-Rev-dex (Isa-VRd) for Newly Diagnosed Non-stem-cell-transplant-eligible myeloma patients (#595): This four-drug phase I study for 27 patients reported […]
Day 2: A busy day at ASH December 2, 2018 Today I attended oral presentations from 8 a.m. to 6 p.m. with a few short breaks to check out posters and exhibits as well as meet with Pharma companies. Let me discuss several findings from several oral presentations (#abstract). Maintenance Therapy with Ninlaro (Ixazomib)….Tourmaline 3 […]
Each year as ASH begins the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup meets to improve treatment approaches related to transplantation in multiple myeloma. This group, representing all significant transplantation centers, discussed incorporating minimal residual disease (MRD) testing to better serve patients. These are some of the questions they reviewed. […]
I look forward every year to Annual ASH Meeting, whether I’m attending in person or experiencing it from home via Twitter, blogs, and professional writers. At ASH we learn new advances in treating, evaluating, and living with myeloma. Immunology has become a central focus of recent ASH meetings and #ASH18 #IMFASH18 will be more of […]
